Published 2023
| Version v1
Publication
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study
Creators
- Bianchi A.
- De Rimini M. L.
- Sciuto R.
- Annovazzi A.
- Di Traglia S.
- Bauckneht M.
- Lanfranchi F.
- Morbelli S.
- Nappi A. G.
- Ferrari C.
- Rubini G.
- Panareo S.
- Urso L.
- Bartolomei M.
- D'arienzo D.
- Valente T.
- Rossetti V.
- Caroli P.
- Matteucci F.
- Arico D.
- Bombaci M.
- Caponnetto D.
- Bertagna F.
- Albano D.
- Dondi F.
- Gusella S.
- Spimpolo A.
- Carriere C.
- Balma M.
- Buschiazzo A.
- Gallicchio R.
- Storto G.
- Ruffini L.
- Scarlattei M.
- Baldari G.
- Cervino A. R.
- Cuppari L.
- Burei M.
- Trifiro G.
- Brugola E.
- Zanini C. A.
- Alessi A.
- Fuoco V.
- Seregni E.
- Deandreis D.
- Liberini V.
- Moreci A. M.
- Ialuna S.
- Pulizzi S.
- Evangelista L.
Contributors
Others:
- Bianchi, A.
- De Rimini, M. L.
- Sciuto, R.
- Annovazzi, A.
- Di Traglia, S.
- Bauckneht, M.
- Lanfranchi, F.
- Morbelli, S.
- Nappi, A. G.
- Ferrari, C.
- Rubini, G.
- Panareo, S.
- Urso, L.
- Bartolomei, M.
- D'Arienzo, D.
- Valente, T.
- Rossetti, V.
- Caroli, P.
- Matteucci, F.
- Arico, D.
- Bombaci, M.
- Caponnetto, D.
- Bertagna, F.
- Albano, D.
- Dondi, F.
- Gusella, S.
- Spimpolo, A.
- Carriere, C.
- Balma, M.
- Buschiazzo, A.
- Gallicchio, R.
- Storto, G.
- Ruffini, L.
- Scarlattei, M.
- Baldari, G.
- Cervino, A. R.
- Cuppari, L.
- Burei, M.
- Trifiro, G.
- Brugola, E.
- Zanini, C. A.
- Alessi, A.
- Fuoco, V.
- Seregni, E.
- Deandreis, D.
- Liberini, V.
- Moreci, A. M.
- Ialuna, S.
- Pulizzi, S.
- Evangelista, L.
Description
Aim: To assess the role of baseline 18F-fluorodeoxyglucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in predicting response to immunotherapy after 6 months and overall survival (OS) in patients with lung cancer (LC) or malignant melanoma (MM). Materials and Methods: Data from a multicenter, retrospective study conducted between March and November 2021 were analyzed. Patients >18 years old with a confirmed diagnosis of LC or MM, who underwent a baseline [18F]FDG-PET/CT within 1-2 months before starting immunotherapy and had a follow-up of at least 12 months were included. PET scans were examined visually and semiquantitatively by physicians at peripheral centers. The metabolic tumor burden (number of lesions with [18F]FDG-uptake) and other parameters were recorded. Clinical response was assessed at 3 and 6 months after starting immunotherapy, and OS was calculated as the time elapsing between the PET scan and death or latest follow-up. Results: The study concerned 177 patients with LC and 101 with MM. Baseline PET/CT was positive in primary or local recurrent lesions in 78.5% and 9.9% of cases, in local/distant lymph nodes in 71.8% and 36.6%, in distant metastases in 58.8% and 84%, respectively, in LC and in MM patients. Among patients with LC, [18F]FDG-uptake in primary/recurrent lung lesions was more often associated with no clinical response to immunotherapy after 6 months than in cases without any tracer uptake. After a mean 21 months, 46.5% of patients with LC and 37.1% with MM had died. A significant correlation emerged between the site/number of [18F]FDG foci and death among patients with LC, but not among those with MM. Conclusions: In patients with LC who are candidates for immunotherapy, baseline [18F]FDG-PET/CT can help to predict response to this therapy after 6 months, and to identify those with a poor prognosis based on their metabolic parameters. For patients with MM, there was only a weak correlation between baseline PET/CT parameters, response to therapy, and survival.
Additional details
Identifiers
- URL
- https://hdl.handle.net/11567/1139475
- URN
- urn:oai:iris.unige.it:11567/1139475
Origin repository
- Origin repository
- UNIGE